Research ArticleBasic Science Investigation
PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference
Melpomeni Fani, Luigi Del Pozzo, Keelara Abiraj, Rosalba Mansi, Maria Luisa Tamma, Renzo Cescato, Beatrice Waser, Wolfgang A. Weber, Jean Claude Reubi and Helmut R. Maecke
Journal of Nuclear Medicine July 2011, 52 (7) 1110-1118; DOI: https://doi.org/10.2967/jnumed.111.087999
Melpomeni Fani
Luigi Del Pozzo
Keelara Abiraj
Rosalba Mansi
Maria Luisa Tamma
Renzo Cescato
Beatrice Waser
Wolfgang A. Weber
Jean Claude Reubi
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 52, Issue 7
July 1, 2011
PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference
Melpomeni Fani, Luigi Del Pozzo, Keelara Abiraj, Rosalba Mansi, Maria Luisa Tamma, Renzo Cescato, Beatrice Waser, Wolfgang A. Weber, Jean Claude Reubi, Helmut R. Maecke
Journal of Nuclear Medicine Jul 2011, 52 (7) 1110-1118; DOI: 10.2967/jnumed.111.087999
PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference
Melpomeni Fani, Luigi Del Pozzo, Keelara Abiraj, Rosalba Mansi, Maria Luisa Tamma, Renzo Cescato, Beatrice Waser, Wolfgang A. Weber, Jean Claude Reubi, Helmut R. Maecke
Journal of Nuclear Medicine Jul 2011, 52 (7) 1110-1118; DOI: 10.2967/jnumed.111.087999
Jump to section
Related Articles
Cited By...
- Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets
- Reply to: Not All Gatekeepers Are Theranostics
- 225Ac-MACROPATATE: A Novel {alpha}-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
- First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
- Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients
- 64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy
- CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer
- A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting
- Somatostatin Receptor Antagonists for Imaging and Therapy
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
- Citius, Altius, Fortius: An Olympian Dream for Theranostics
- Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers
- N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of 68Ga- and 64Cu-Labeled Peptides for PET Imaging
- Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
- Radiopeptide Imaging and Therapy in Europe